Mouse study finds tirzepatide slowed obesity-associated breast cancer growth

Anti-motor drug tirizeptide, zipbound for marketing and obesity for diabetes, reduced the development of obesity related breast cancer in a mouse model, being presented on Saturday according to a study on Saturday Endo 2025Annual meeting of Endocrine Society at San Francisco, California.

“Obesity is an important risk factor Breast cancerAnd when it is very initial data, our study in mice shows that it new opponents-obesity Drugs can be a way to reduce the risk of breast cancer or improve results, “the author of the study said a candidate of Amanda Kusinskas, BS, D.D.D.D.

Current research has shown that obesity can cause breast cancer results that do not cause obesity compared to those, and weight loss can improve results. However, there are many challenges with traditional weight loss methods.

Kusinskus and colleagues took advantage of tirzepetide, one of the new class of effective anti-obesity drugs that targets GLP-1 (Glucagon-like Peptide 1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Researchers tried to find out whether Tirzepatide would reduce the growth of breast cancer associated with obesity.

This mouse study consisted of 16 rats. 9-week C57BL/6 mice fed 40% high-fat diet And placed in a warm environment to induce obesity. At the age of 32 weeks, obese mice were injected randomly for 16 weeks for 16 weeks or randomly. The tumor volume was measured twice weekly.

Researchers found that anti-motor drug drug reduced body weight and body fat by about 20% in mice similar to the amount of weight loss received by women on this medicine. They found that this was mainly due to loss of fat mass, with a decrease in fat depot weight compared to control.

Anti-motor drug also reduced the amount of tumor compared to control. At the end of the study, the researchers found that the amount of tumor was quite correlated. Body weightThe total fat mass and the amount of fat stored in the liver.

“While these are very early results, they suggest that this new anti -obesity drug could also have a beneficial effect on the results of breast cancer,” Kusinskas said.

Dr. at North Carolina University in Chapel Hill. Studies are underway in collaboration with Steve Hurvinging Lab Decrease in load From tumor-specific effects of tirzepatide.